Louis Garguilo
ARTICLES BY LOUIS
-
![NexusPlantRendering]( "Roadmap To U.S. Drug Manufacturing: Outsource And Build At Home")
6/17/2020Nexus Pharmaceuticals has laid out a roadmap - and is living proof - we can develop and manufacture even generics in the U.S. And that goes for both in-house and at CMOs.
-
![BioCentriqrendering]( "New Jersey Solutions For Cell And Gene Development and Manufacturing")
6/12/2020New Jersey’s first university-based, cell-and-gene-therapy development and manufacturing innovation center for-hire, was founded on solving three critical industry needs.
-
![US-ChinaDice]( "Drug Tariffing: How Trade Policy And Politics Manipulate Your Outsourcing")
6/8/2020Tariffs, historic trade policy, politics: Most likely not top-of-mind right now. Here’s why they should be, particularly for younger professionals at U.S. biotechs leveraging CDMOs.
-
![Pills Medication]( "The Oral Solid Dose Path To U.S. Partnerships")
5/28/2020OSD drugs are receiving the benefits of new technologies, formulation ideas, and other processing innovations. Can innovation pare COGs to open up more production in the U.S.? Here's our assessment.
-
![iStock-1131848229]( "Common Drugs Now Made In America!")
5/22/2020It begins in a typical flash hurled by our hyrdoxycloriquine President. A U.S. drug manufacturer gets up to $812 million in federal funding for advanced manufacturing of America's most essential medicines. More politics or real progress?
-
![Money]( "Circle Economics And A Man Made In America")
5/21/2020Inspiration and "circle economics" could help shape your outsourcing decisions. And who knows: It all might end up supporting a more robust national drug-manufacturing infrastructure.
-
![Japan Globe]( "View From Tokyo: Rise Of The “Values” Chain")
5/15/2020The Wuhan coronavirus outbreak has brokered a virulent "value" chain debate around the world, including a global CDMO's CEO situated in Tokyo.
-
![COVID 19]( "Pfizer Shifts Outsourcing And Communication To Fight COVID-19")
5/14/2020Pfizer’s speaking in real-time – actually forward-looking pronouncements of manufacturing intentions and locations – is refreshing, and should be applauded. Does this represent an industry "shift"?
-
![Growing Steps Trending Up]( "As Your CDMOs Grow In Value, Their Challenges Pile Up")
5/11/2020The CDMO market is estimated to grow to $157.7 billion in 2025, a compound annual growth rate (CAGR) of 6.9%, according to an industry report. But what kind of CDMO growth is best for Outsourced Pharma readers?
-
![The Raw Materials Of A Supply-Chain Revolution]( "The Raw Materials Of A Supply-Chain Revolution")
5/6/2020To diversify China-dependent supply chains and procure materials, API and products in the U.S., we'd literally need to start digging.
Louis Garguilo
Click here to e-mail Louis
Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.
Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.